Biosurf Biotech Secures Tens of Millions in Series B+ Funding to Advance Bio-Material Surface Modification Platform for Health Applications

On August 15, 2022, Jiangsu Biosurf Biotech Co., LTD (hereinafter referred to as “Biosurf”) officially announced the completion ofTens of millions in Series B+ financing. This round of financing is led by strategic investorsYuanBio Venture CapitalLead investor,LH VenturesCo-investment.

This round of financing will further propel Jiangsu Biosurf Biotech Co., LTD to build a biomaterial surface modification technology platform dedicated to healthy living, intensify efforts to attract and cultivate high-level R&D talent, and continuously invest in expanding R&D facilities and upgrading R&D equipment. The company aims to establish a high-caliber platform for customized product R&D, a testing and inspection center, and a regulatory science base, thereby promoting the development of an industrial cluster for key raw materials upstream of the medical device sector. These initiatives will comprehensively empower the localization of high-end medical devices, fill domestic gaps in independently developed products, continue to expand surface modification technology development and product commercialization targeting high-value life science consumables to address industry pain points, and strengthen the company’s comprehensive digital infrastructure to continuously enhance management efficiency and standards.

“We sincerely appreciate YuanBio Venture Capital and LH Ventures for their recognition and support of Biosurf.”Professor Chen Hong, Founder of BiosurfHe stated, “Our team has accumulated extensive research expertise in the field of biomaterial surface modification. We are now seizing a surge in market demand. Jiangsu Biosurf Biotech Co., LTD will leverage its internationally competitive products and services to facilitate the mass commercialization of domestically produced implantable and interventional devices featuring lubricious, anticoagulant, and antibacterial coatings. I have always believed that resolving critical bottlenecks in the industry relies on the sustained R&D efforts of leading enterprises in specialized sectors. Therefore, with this round of financing, we will increase investment in upgrading R&D facilities at our Technology R&D Center and attracting high-caliber R&D personnel. Our goal is to establish a world-class platform for surface modification technology and R&D, promote the development of an upstream cluster of key raw materials, and empower Suzhou’s No. 1 priority industry.”

Gu Leimin, Partner at YuanBio Venture Capital“It is acknowledged that Professor Chen Hong and her team have conducted extensive exploration and built a solid foundation in the field of biomaterial surface and interface engineering, earning international acclaim. Biosurf’s strategic layout demonstrates both breadth and depth, spanning from molecular design of functional coatings to precise formulation for diverse material systems, from laboratory-scale equipment to large-scale manufacturing facilities, and from testing and inspection methodologies to product quality standards. With the continuous upgrading and iteration of medical devices, the demand for medical-grade coatings is expected to grow increasingly robust. We are confident that Biosurf will emerge as a leading Chinese enterprise in this emerging market.”

Dr. Xin Xie, Partner at LH Ventures“He stated, ‘High-quality functionalized surface coatings are critical for implantable and interventional medical devices. With years of in-depth expertise in the field of biomaterial surfaces and interfaces, Jiangsu Biosurf Biotech Co., LTD has established a comprehensive industrial technology service platform for hydrophilic lubricious, antimicrobial, and anticoagulant coatings, breaking foreign technological monopolies and achieving import substitution. We look forward to Biosurf supporting the rapid advancement of China’s medical device industry across broader domains.’”

Jiangsu Biosurf Biotech Co., LTD leverages the founder’s over two decades of professional expertise and academic influence in the field of biomaterial surface and interface science, both domestically and internationally. The company is dedicated to the innovative development of surface modification technologies for biomaterials, creating high-end functional coatings and related products with independent intellectual property rights and international competitiveness. Since its establishment in 2017, Biosurf has entered the market by providing comprehensive solutions for surface coating technologies for implantable and interventional medical devices, which have high technical barriers. It has built a specialized technical service platform covering the entire industrial chain of medical functional coatings, breaking foreign technological monopolies, filling multiple domestic gaps, and successfully achieving import substitution. According to public data from the China National Intellectual Property Administration, Biosurf has become the enterprise with the highest number of patent applications and grants in China within the global medical coating industry. The company also participates in regulatory science research and the establishment of inspection and testing standards for coated medical devices. Biosurf has formed an integrated technical service and innovative product platform centered on biomaterial surface modification technology, encompassing R&D and production of coating materials, advanced manufacturing of coating equipment, development and contract manufacturing of coating processes, development of coating quality analysis instruments and inspection/testing services, as well as R&D of new coated products. By building an internationally leading brand for autonomously controllable biofunctional coatings and related products, Biosurf drives the high-quality development of the health industry.

YuanBio Venture Capital is an investment firm focused on early-stage and growth-stage companies in the healthcare sector. Headquartered in Suzhou BioBAY, it maintains a global reach. To date, YuanBio has invested in over 140 outstanding enterprises in the life and health sectors, covering four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 15 of its portfolio companies having listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a world-class team of scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

LH Ventures, established in 2018, currently manages multiple RMB and USD funds with assets under management totaling RMB 2.5 billion. Backed by an experienced management team, the firm has facilitated successful IPOs of numerous portfolio companies on both the A-share market and NASDAQ, achieving internal rates of return (IRR) that rank among the top in the industry. With a global perspective, LH Ventures specializes in value-added investing and adheres to long-term value investment principles, focusing strategically on key sectors such as intelligent technology and biomedicine. Operating across China and the United States, the firm leverages capital to drive industrial consolidation and has built a comprehensive ecosystem around core industries in China.